YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[Hands holding up columns of bar graph] We Are UBS Global Research has constructed a 56-stock basket of U.S. companies with higher forward growth, stronger cash-flow profitability and improving earnings momentum, arguing that valuations fo…
Liquidia (LQDA) moved into the spotlight after a new court ruling in its patent fight with United Therapeutics over YUTREPIA, raising fresh questions about future labeling and market access. Recent trading reflects that uncertainty. Liquid…
[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov Liquidia (LQDA [https://seekingalpha.com/symbol/LQDA]) is heading for its worst weekly decline on Friday after a legal setback in its patent dispute with United Therap…
Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR)…
Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index falling 1% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Check out some of the companies making the biggest moves midday: Accenture — The global professional services company soared 18% following fiscal fourth-quarter results. Revenue of $18.7 billion exceeded the company's guidance of $17.8 bil…
Liquidia Corporation LQDA suffered a major setback after the U.S. District Court for the District of Delaware ruled that two claims of United Therapeutics' UTHR '327 patent are valid and infringed by Liquidia's lead drug Yutrepia. The ruli…
United Therapeutics UTHR announced that it has received a favorable ruling in its patent litigation against Liquidia Technologies LQDA concerning the latter's lead product, Yutrepia, a dry-powder inhaled formulation of treprostinil. UTHR s…
Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled b…
Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today What Happened? Shares of biotechnology company United Therapeutics (NASDAQ:UTHR) jumped 13.6% in the afternoon session after a federal district court ruled that competitor Liqu…
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., September 30, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of…
A district judge ruled Wednesday that Liquidia infringed on United Therapeutics' patents with its drug, Yutrepia. The stocks diverged. Continue Reading
Healthcare stocks declined late Wednesday afternoon with the NYSE Healthcare Index and the State Str PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Investing.com -- Liquidia Corp shares fell Wednesday after a U.S. District Court in Delaware ruled the company infringed two patent claims held by United Therapeutics Corp. United Therapeutics shares rose more than 13%. Before you buy NVID…
Liquidia Technologies, Inc. District Court ruled that two of the six claims asserted against Liquidia are valid and infringed Parties directed to submit form of judgment, specifying the proposed remedy, for the District Court's considerati…
Check out the companies making the biggest moves midday: Rogers — The maker of circuit materials surged 10% on better-than-expected earnings guidance. The company sees full-year earnings around $3.80 per share, excluding certain items, abo…
Liquidia Corporation LQDA and Alkermes plc ALKS are both commercial-stage biopharmaceutical companies with specialty therapies and a similar mid-cap biotech investor profile. LQDA is focused on developing and commercializing therapies for…
Liquidia Corporation LQDA is gaining strong commercial momentum with Yutrepia, but intensifying competition in the pulmonary arterial hypertension (PAH) market could make it increasingly challenging for the drug to sustain its growth traje…
Shares of Liquidia Corporation LQDA have lost 13.9% in a month against the industry's growth of 1.5%. The stock has lagged the broader sector and the S&P 500 Index. The selloff accelerated after Liquidia reported second-quarter results on…
Liquidia Corporation LQDA recently announced that the FDA has granted Fast Track designation to Yutrepia (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). Lead drug Yutr…
The U.S. Food and Drug Administration has granted Fast Track designation to Liquidia (LQDA) therapy YUTREPIA for Raynaud's phenomenon in systemic sclerosis, drawing investor attention to the stock and its rare disease pipeline. Liquidia's…
Summers Value Partners, a boutique investment firm, noted in its Q2 2026 investor update that The Summers Value Fund delivered strong results in the quarter, returning 41.7% net, outperforming the Russell 2000 Index ETF (IWM), which return…
Liquidia Technologies, Inc. MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respira…
Liquidia Corporation LQDA is counting on its lead drug, Yutrepia, to sustain its strong commercial momentum despite intense competition in the pulmonary arterial hypertension (PAH) market. Yutrepia is an inhaled dry-powder formulation of t…
Liquidia Corporation LQDA and Insmed INSM are both commercial-stage biopharmaceutical companies with a focus on developing innovative treatments for serious diseases. LQDA is focused on developing and commercializing therapies for pulmonar…
Liquidia Corporation LQDA is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (P…
Liquidia Corporation's LQDA lead drug, Yutrepia, has delivered a strong commercial performance since its launch, generating approximately $300.3 million in sales during the first half of 2026. Launched in June 2025, Yutrepia received FDA a…
Shares of Liquidia Corporation LQDA have lost 15.4% since the company reported second-quarter results on Aug. 11. Liquidia reported second-quarter 2026 earnings of 74 cents per share, which beat the Zacks Consensus Estimate of 70 cents. Th…
Greenhaven Road Capital, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund achieved an approximate 11% net return in the second quarter, indicating pro…
Key Points The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.10 stocks we like better than Liquidia › Liquidia(NASDAQ: LQDA) hasn't been the healthiest healthc…
Liquidia Corporation LQDA reported second-quarter 2026 earnings per share (EPS) of 74 cents, which topped the Zacks Consensus Estimate of 70 cents. In the year-ago quarter, the company reported a loss per share of 49 cents. Total revenues…
Liquidia Corporation Q2 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pi…
Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits. Continue Reading
Shares of Alkermes ALKS have risen 26.5% in the past three months, driven by strong sales growth across its proprietary product portfolio and continued progress in its clinical pipeline. Alkermes' proprietary products include Vivitrol for…
Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. Coll…
Belite Bio BLTE announced that the FDA has accepted the new drug application (NDA) seeking approval for its lead candidate, tinlarebant, for the treatment of patients with Stargardt Disease type I (STGD1). With the FDA granting a priority…